Core Insights - Pelthos Therapeutics Inc. will have its CEO, Scott Plesha, present at the Oppenheimer 36th Annual Healthcare Life Sciences conference on February 26, 2026 [1] - The company is focused on commercializing innovative therapeutic products for unmet patient needs, particularly in the area of cutaneous infectious diseases [3] Company Overview - Pelthos Therapeutics is a commercial-stage biopharmaceutical company with a portfolio that includes ZELSUVMI™ (berdazimer) topical gel, the first and only prescription therapy approved for home use to treat Molluscum contagiosum [3] - Other products in the company's portfolio include Xepi® (ozenoxacin) Cream for impetigo and Xeglyze® (abametapir) for head lice [3] Investor Engagement - The management team will host one-on-one meetings with investors during the conference, and interested investors can contact their Oppenheimer representative to arrange meetings [2] - A webcast of the presentation will be available on the company's website, with a replay accessible for 90 days following the event [2]
Pelthos Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference
Globenewswire·2026-02-23 13:00